Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Royalty PharmaRPRX -0.98%75 Days Sales Outstanding is 116.97 as of Jun. 2026. GuruFocus rates RPRX with a GF Score™ of 75/100 and a GF Value™ of $42.83 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 841 Biotechnology companies, Royalty Pharma ranks worse than 118905.95% on this metric.
Royalty Pharma's average Accounts Receivable for the
three
months ended in Jun. 2026 was $864 Mil. Royalty Pharma's Revenue for the
three
months ended in Jun. 2026 was $674 Mil.
Hence, Royalty Pharma's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 116.97.
The historical rank and industry rank for Royalty Pharma's Days Sales Outstanding or its related term are showing as below:
RPRX's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.98 * Ranked among companies with meaningful Days Sales Outstanding only.
Royalty Pharma's Days Sales Outstanding
declined
from Jun. 2025 (127.02) to Jun. 2026 (116.97).
Royalty Pharma (NAS:RPRX) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Royalty Pharma Days Sales Outstanding Related Terms
Royalty Pharma Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Royalty Pharma's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RPRX vs INSM, BNTX, INCY: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Royalty Pharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 116.97 mean?
Royalty Pharma (RPRX) has a Days Sales Outstanding of 116.97 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Royalty Pharma and its competitors. According to the industry distribution chart, Royalty Pharma ranks #999999 out of 841 companies in the Biotechnology industry.
Is Royalty Pharma's Days Sales Outstanding too high?
Royalty Pharma's current Days Sales Outstanding is 116.97. The Biotechnology industry median Days Sales Outstanding is 68.98. Royalty Pharma's value of 116.97 is 69.6% above this industry median. Based on the distribution chart, Royalty Pharma ranks #999999 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Royalty Pharma has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Days Sales Outstanding compare to INSM and BNTX?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #999999 out of 841 companies for Days Sales Outstanding. This places Royalty Pharma in the lower half of its industry. The industry median Days Sales Outstanding is 68.98. Royalty Pharma's value of 116.97 is 69.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Royalty Pharma's current Days Sales Outstanding of 116.97 is 69.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Royalty Pharma and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Royalty Pharma's current Days Sales Outstanding is 116.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (RPRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $42.83, compared to a current price of $58.47 — trading 36.5% above its estimated fair value. The current Days Sales Outstanding is 116.97 and 69.6% above the Biotechnology industry median of 68.98. Royalty Pharma's overall GF Score™ is 75/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Royalty Pharma (RPRX), the current Days Sales Outstanding is 116.97 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (RPRX) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of $58.47 is trading 36.5% above its estimated GF Value™ of $42.83.
GuruFocus considers Royalty Pharma to be Significantly Overvalued.
Key valuation signals for RPRX:
Days Sales Outstanding: 116.97
GF Value™: $42.83 vs. price of $58.47 (36.5% above fair value)
Industry Position: 69.6% above the Biotechnology median (#999999 of 841)
No single metric tells the full story. See the RPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
75GF Score
Get the complete analysis for RPRX
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPRX has been successfully added to your 
